An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 12 years has built and turned-around three pharmaceutical companies. He led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent company, Alvogen Group. During his 5.5 year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries. In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Under Doug’s leadership, Pernix raised $465 million of capital. From November 2017 to July 2020, Doug was a Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.Doug Drysdale is the Chief Executive Officer of Cybin. During Doug’s 30+ years of experience in the healthcare sector, he has built cohesive management teams, recruited board members, created multinational operations, and has raised around $4 billion of both public and private capital. As founding CEO of Alvogen, Doug led the company from inception to around $500mm in revenues, across 35 countries. Previously, Doug was Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008. In 2012 Doug was named E&Y Entrepreneur of the Year.